Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uses of cycloastragenol in preparation of chronic renal failure treatment drugs

A technology of cycloastragalus and chronic renal failure, applied in the field of medicine, can solve the problems such as the clinical application of the biological activity of cycloastragalus against renal failure, which can improve the treatment effect and the quality of life, reduce the renal coefficient and the effect of full effect

Pending Publication Date: 2017-07-14
LUNAN PHARMA GROUP CORPORATION
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] So far, there is no research on the biological activity of cycloastragenol against renal failure and its clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of cycloastragenol in preparation of chronic renal failure treatment drugs
  • Uses of cycloastragenol in preparation of chronic renal failure treatment drugs
  • Uses of cycloastragenol in preparation of chronic renal failure treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 In vivo pharmacodynamics test of cycloastragenol in treating renal failure

[0025] 1. Purpose of the test

[0026] To investigate the effectiveness of cycloastragenol in the treatment of renal failure, and to provide a basis for the research, development and clinical application of cycloastragenol.

[0027] 2. Test site

[0028] The barrier system of the Institute of New Drug Pharmacodynamics, Pharmacology Center, Shandong New Times Pharmaceutical Co., Ltd.

[0029] 3. Test materials

[0030] 3.1 Test drugs

[0031] Cycloastragenol 98% HHQC-20150119 Xi'an Haoxuan Biotechnology.

[0032] 3.2 Positive control drug

[0033] Astragalus injection 141126A3 Shineway Pharmaceutical Group.

[0034] 3.3 Other drugs and reagents

[0035] Adenine: purity ≥ 98%, Shanghai Bojing Chemical, batch number: 20120510. Urine protein quantitative kit: Nanjing Jiancheng Biotechnology Co., Ltd., batch number: 20141220.

[0036] 3.4 Test animals

[0037] SPF grade SD rats, ...

Embodiment 2

[0106] The preparation of embodiment 2 injection

[0107]

[0108] Preparation process: mix the prescribed amount of propylene glycol and ethanol evenly, add cycloastragenol, stir to dissolve, add the prescribed amount of 0.9% sodium chloride solution, stir evenly, add 0.5% activated carbon for needles, stir, and decarbonize to obtain the product.

Embodiment 3

[0109] The preparation of embodiment 3 injection

[0110]

[0111] Preparation process: add cycloastragenol to the mixed solution of PEG-400 and ethanol in the prescribed amount, stir to dissolve, add 0.9% sodium chloride solution to 10L, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize, and obtain .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the field of medicine, and particularly relates to uses of cycloastragenol in preparation of chronic renal failure treatment drugs. According to the present invention, cycloastragenol is the aglycone of astragaloside A, and has advantages in biological membrane permeation and gastrointestinal tract absorption compared to astragaloside A due to the relatively small molecular weight and the strong lipophilicity, and the test results show that cycloastragenol can change various physiologic indexes of chronic renal failure rates so as to provide great application prospects in the treatment of chronic renal failure.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the medical use of cycloastragenol, in particular to the use of cycloastragenol in preparing medicine for treating chronic renal failure. Background technique [0002] Chronic Renal Failure (CRF) is the late stage of various primary and secondary kidney diseases. The kidney parenchyma is severely damaged, resulting in the retention of nitrogen metabolites, imbalance of water, electrolyte and acid-base balance, and endocrine disorders. a clinical syndrome. Although the development of hemodialysis, peritoneal dialysis and kidney transplantation has opened up a new way for the treatment of CRF and prolongs the life of patients, there are problems of high cost, insufficient kidney source and various complications, and it has not been popularized in developing countries. , seeking low-cost therapeutic drugs is the main direction of research by medical workers. [0003] Astragalus, also known a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P13/12
CPCA61K31/58
Inventor 张贵民宋洪运杜丙源贺可文谭玉军王现珍吕圆圆
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com